Navigation Links
BIO-key Reports Second Quarter 2007 Results
Date:9/3/2007

months of 2006.

Liquidity and Capital Resources

Consolidated cash and cash equivalents at June 30, 2007 was $0.6 million.

During the second quarter, BIO-key announced the sale of its Fire/EMS Services Division to ZOLL Data Systems for $7 million in cash. Approximately $4.3 million of the transaction's proceeds were used to repay all of the Company's senior secured debt obligations. Additionally, $0.4 million of the proceeds were placed in escrow pursuant to the Purchase Agreement, and are to be remitted to BIO-key under the terms of the agreement.

DePasquale concluded, "We believe the sale of our Fire/EMS Services businesses to ZOLL Data Systems is a confirmation of what we have been building over the last three years. We sold the unit -- which we viewed as a non-strategic asset -- for over two times what we paid as part of our acquisition of Aether Systems' Mobile Government Division business in 2004. We then applied the proceeds to effectively eliminate all of our senior secured debt obligations and are now positioned with a stronger balance sheet and improved liquidity. We are now better situated to evaluate growth opportunities that will benefit the company in the long-term and grow shareholder value."

Conference Call Details

BIO-key has scheduled a call for Wednesday, August 15th at 9:00 a.m. Eastern Time to discuss second quarter 2007 financial results. Dialing 303-262-2211 and asking for the BIO-key call at least 10 minutes prior to the start time can access the conference call live. The conference call will also be broadcast live over the Internet by logging onto http://www.bio-key.com. A telephonic replay of the conference call will be available through August 22, 2007 and may be accessed by dialing 303-590-3000 and using the pass code 11095677#. Additionally, an archive of the webcast will be available shortly after completion of the call on the Company's website ('/>"/>

SOURCE BIO-key International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Tulane researcher reports on origin of deadly fever outbreak
2. Many cats unaffected by catnip, C&EN reports
3. Breast implants not associated with cancer risk, study reports
4. Arsenic in chicken feed may pose health risks to humans, C&EN reports
5. New study reports hotel guests at risk from carbon monoxide poisoning
6. Researchers discover molecule that causes secondary stroke
7. Important discovery about second most fatal cancer
8. Second messenger NAADP shows fast, dose-related impact on satiety cycle
9. Female volunteers prepare for a second bedrest
10. Overbearing colored light may reveal a second mechanism by which birds interpret magnetic signals
11. Nanosecond-scale release of stinging jellyfish nematocysts
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2